CSIMarket
 
Applied Molecular Transport Inc   (AMTI)
Other Ticker:  
 
 
Price: $0.2630 $-0.04 -14.304%
Day's High: $0.313 Week Perf: -4.19 %
Day's Low: $ 0.26 30 Day Perf: 59.98 %
Volume (M): 240 52 Wk High: $ 0.49
Volume (M$): $ 63 52 Wk Avg: $0.25
Open: $0.31 52 Wk Low: $0.13



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 40
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -75
 Cash Flow (TTM) (Millions $) -59
 Capital Exp. (TTM) (Millions $) 0

Applied Molecular Transport Inc
Applied Molecular Transport Inc is a biotechnology company that focuses on developing and commercializing transformative oral biologic therapeutics. The company leverages its proprietary technology platform to transport large molecule drugs across the gut barrier into the bloodstream, increasing their bioavailability and therapeutic effectiveness. Their innovative approach has the potential to revolutionize the delivery of biologic drugs, which are traditionally administered via injection or infusion. Applied Molecular Transport Inc aims to address significant unmet medical needs and improve patient outcomes through their advanced drug delivery technology.


   Company Address: 1209 Orange Street Wilmington 19801 DE
   Company Phone Number: 392-0420   Stock Exchange / Ticker: NASDAQ AMTI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Applied Molecular Transport Inc

Applied Molecular Transport Inc (AMTI) Takes the Lead in the Booming Major Pharmaceutical Preparations Market with Impressive Fiscal Period Earnings

Interpreting the Financial Results of Applied Molecular Transport Inc.
It is no secret that the pharmaceutical sector has experienced its fair share of ups and downs in recent times. As the earnings cycle of fiscal July to September 30, 2023, comes to a close, most entities have disclosed their respective financial results. Among them, Applied Molecular Transport Inc. (AMTI) stands out.

Applied Molecular Transport Inc

Applied Molecular Transport Inc?s Fiscal Q2 Results: Operating Loss Shows Inspired Turnaround, Boosting Investor Confidence



The financial results of Applied Molecular Transport Inc (AMTI) for the earnings cycle of fiscal April to June 30, 2023, have surprised stockholders and market observers alike. While top-line moderations were not anticipated, the company's operating loss experienced a significant improvement compared to the previous year. This unexpected positive trend has generated optimism for the future prospects of Applied Molecular Transport Inc.
Improved Operating Loss:
During the mentioned period, Applied Molecular Transport Inc recorded an operating loss of $-17.732 million. Although this still represents a loss, it is a remarkable improvement compared to the operating loss of $-36.022 million incurred during the comparable period a year earlier. This reduction in operating loss signals the company's efforts to manage costs and streamline its operations, instilling confidence among investors and market observers.

Applied Molecular Transport Inc

Applied Molecular Transport Inc's Negative Financial Performance Raises Concerns Among Investors

Applied Molecular Transport Inc (AMTI) has recently released a financial report, which shows that the company has incurred a cumulative net loss of $-112 million during the 12 months that ended in the first quarter of 2023. This negative financial performance resulted in a negative return on investment (ROI) of -111.56%. Unfortunately, the total ranking of return on investment has deteriorated when compared to the fourth quarter of 2022, dropping from 0 to 4381.
An analysis of the healthcare sector shows that Applied Molecular Transport is among the 830 other companies that had a higher ROI. This is an indication that the company needs to improve its financial position compared to its competitors. The stockholders didn't expect any significant changes in the top-line during the earnings season from January to March 2023. However, investors were interested in monitoring the operating deficit of $-28.483 million during the same period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com